A framework for understanding and targeting residual disease in oncogene-driven solid cancers

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Molecular targeted therapy shows promise for improving cancer patient survival.
• Complete and durable responses to targeted therapy are infrequent in advanced solid cancers.
• Most targeted therapies leave residual disease, leading to tumor progression and limited survival.

Purpose of the Study:

• To highlight the need for understanding the molecular basis of residual disease.
• To propose strategies for minimizing or eliminating residual disease.
• To advocate for a shift towards pre-emptive therapeutic paradigms.

Main Methods:

• Discussion of current challenges in targeted cancer therapy.
• Analysis of the limitations of existing therapeutic approaches.
• Conceptual framework for a pre-emptive strategy against residual disease.

Main Results:

• Residual disease is a common outcome of targeted therapy in advanced solid cancers.
• Current approaches often result in temporary disease control rather than a cure.
• Understanding residual disease is key to improving long-term patient survival.

Conclusions:

• A deeper understanding of residual disease molecular mechanisms is essential.
• A pre-emptive strategy targeting residual disease is proposed.
• This shift aims to achieve chronic disease control or a cure for advanced solid cancers.